questionText: To ask the Secretary of State for Health and Social Care, with reference to the decision by the Medicines and Healthcare products Regulatory Agency on 22 August 2024 to licence lecanemab for patients with early stage Alzheimer's disease, what discussions 
answerText: Department officials have had a number of conversations with colleagues in NHS England about their plans to support the adoption of any licensed and National Institute for Health and Care Excellence (NICE) recommended treatment for Alzheimer’s disease.The...
heading: Alzheimer's Disease: Drugs